Re: How to account for M-M in the presence of Ka>Ke constraint in PopPK model
Lei, Paulo,
There is no need to feel any pain due to "flip-flop" when elimination is by a mixed order process. The "flip-flop" only causes difficulty in assigning 'ka' and 'k' because of the symmetry of the sum of two exponentials. If you have a mixed order process there is no 'k' and therefore no symmetry of exponentials and therefore no "flip-flop".
Best wishes,
Nick
Quoted reply history
On 9/07/2015 7:57 a.m., Paolo Denti wrote:
> Dear Lei,
>
> I feel your pain, cuz I have also battled with models with stubborn flip-flop and I started concocting all sort of codes similar to yours to prevent it - you can probably find some desperate posts of mine about this on NMUSERS :).
>
> In my experience, the only code that sort of works without causing too many side-effects is the one that prevents flip-flop of the typical values (the THETAs). Unfortunately, this does not work every time, but all the other codes accounting for individual parameters (such as the one you propose) introduce funny correlations between the parameters and the ETAs, they reshape the between-subject variability, and they may end up causing more trouble than they solve. In your case with nonlinear clearance, it may be even more complicated than usual.
>
> In my experience, the best option is to use priors on ka and volume, even weakly informative. These should help stabilising your model. Adding priors may seem "artificial", but if you think about it, it is doing exactly what you are trying to achieve with all these tricky codes. One cannot solve the flip-flop problem only with data from oral administration, the only way is to add external information, like the fact that you expect ka to be larger than ke, or include IV data that helps you identify the correct value of volume. With the priors you do just that, and in a more natural way than "cheating" NONMEM with funny codes.
>
> Good luck!
> Paolo
>
> On 2015/07/08 22:41, Lei Diao wrote:
>
> > Dear NONMEM Users,
> >
> > I have a popPK model for which the Ka is constrained to be larger than Ke at the individual level to avoid flip-flop. The question is that if there is an additional nonlinear clearance component (M-M), how should I constrain between the absorption rate (KA) and terminal phase elimination rate (KE) since nonlinear clearance causes the KE to change with time? Is there any reference on this topic?
> >
> > KA and KE constraining in the absence of nonlinear clearance in NM code:
> >
> > KE=((K+K23+K32)-SQRT((K+K23+K32)*(K+K23+K32)-4*K*K32))/2
> >
> > KA=KE+THETA(5)*EXP(ETA(3))
> >
> > Thanks a lot for your input!
> >
> > Lei Diao
> >
> > Biogen
>
> --
> ------------------------------------------------
> Paolo Denti, PhD
> Pharmacometrics Group
> Division of Clinical Pharmacology
> Department of Medicine
> University of Cape Town
>
> K45 Old Main Building
> Groote Schuur Hospital
> Observatory, Cape Town
> 7925 South Africa
> phone: +27 21 404 7719
> fax: +27 21 448 1989
> email:[email protected]
> ------------------------------------------------
> ------------------------------------------------------------------------
> UNIVERSITY OF CAPE TOWN
>
> This e-mail is subject to the UCT ICT policies and e-mail disclaimer published on our website at http://www.uct.ac.za/about/policies/emaildisclaimer/ or obtainable from +27 21 650 9111. This e-mail is intended only for the person(s) to whom it is addressed. If the e-mail has reached you in error, please notify the author. If you are not the intended recipient of the e-mail you may not use, disclose, copy, redirect or print the content. If this e-mail is not related to the business of UCT it is sent by the sender in the sender's individual capacity.
--
Nick Holford, Professor Clinical Pharmacology
Dept Pharmacology & Clinical Pharmacology, Bldg 503 Room 302A
University of Auckland,85 Park Rd,Private Bag 92019,Auckland,New Zealand
office:+64(9)923-6730 mobile:NZ+64(21)46 23 53 FR+33(7)80 48 55 50
email: [email protected]
http://holford.fmhs.auckland.ac.nz/
Holford SD, Allegaert K, Anderson BJ, Kukanich B, Sousa AB, Steinman A, Pypendop,
B., Mehvar, R., Giorgi, M., Holford,N.H.G. Parent-metabolite pharmacokinetic models
- tests of assumptions and predictions. Journal of Pharmacology & Clinical
Toxicology. 2014;2(2):1023-34.
Holford N. Clinical pharmacology = disease progression + drug action. Br J Clin
Pharmacol. 2015;79(1):18-27.